AVADEL PHARMACEUTICALS (AVDL) Stock Price, Quote, News and Overview
NASDAQ:AVDL - Nasdaq - IE00BDGMC594 - Common Stock - Currency: USD
AVDL Quote, Performance and Key Statistics
AVADEL PHARMACEUTICALS
NASDAQ:AVDL (2/5/2025, 10:51:09 AM)
8.43
+0.25 (+3.06%)
The current stock price of AVDL is 8.43 USD. In the past month the price decreased by -26.04%. In the past year, price decreased by -43.27%.
AVDL Latest News, Press Releases and Analysis
Avadel Pharmaceuticals Appoints Sev Melkonian as Vice President of Patient Services, Distribution, and Reimbursement
DUBLIN, Ireland, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming...
There May Still Be Time to Get in on These 3 Trending Biotechs
Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.
Avadel Pharmaceuticals Misses Earnings Estimates But Posts 150% Sales Increase From Narcolepsy Drug LUMRYZ
Avadel Pharmaceuticals missed the fourth quarter sales estimate by 5.12%. Still, the sales of its narcolepsy drug, LUMRYZ rose by 150% YoY.
Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch
-- Approximately $50.0 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives,...
Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8
DUBLIN, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to...
AVDL Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 81.85 | 790.22B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 29.38 | 384.78B | ||
| JNJ | JOHNSON & JOHNSON | 15.4 | 370.29B | ||
| MRK | MERCK & CO. INC. | 11.58 | 223.82B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.76 | 217.94B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.3 | 216.25B | ||
| PFE | PFIZER INC | 8.55 | 150.63B | ||
| SNY | SANOFI-ADR | 13.62 | 135.21B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 51.06 | 121.16B | ||
| ZTS | ZOETIS INC | 30.2 | 78.49B | ||
| GSK | GSK PLC-SPON ADR | 9.05 | 76.44B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.09 | 42.39B |
Related stock screener links
About AVDL
Company Profile
Avadel Pharmaceuticals PLC is a IE-based company operating in Pharmaceuticals industry. The company is headquartered in Dublin, Dublin and currently employs 154 full-time employees. Avadel Pharmaceuticals PLC is a biopharmaceutical company. The firm's product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
Company Info
AVADEL PHARMACEUTICALS
Block 10-1 Blanchardstown Corporate Park, Ballycoolin
DUBLIN DUBLIN D02 IE
CEO: Gregory J. Divis
Employees: 154
Company Website: https://www.avadel.com/
Investor Relations: https://investors.avadel.com
Phone: 35319015201
AVDL FAQ
What is the stock price of AVDL?
The current stock price of AVDL is 8.43 USD.
What is the symbol for AVADEL PHARMACEUTICALS stock?
The exchange symbol of AVADEL PHARMACEUTICALS is AVDL and it is listed on the Nasdaq exchange.
On which exchange is AVDL stock listed?
AVDL stock is listed on the Nasdaq exchange.
Is AVDL a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for AVDL, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of AVDL.
Does AVDL stock pay dividends?
AVDL does not pay a dividend.
What is the Price/Earnings (PE) ratio of AVDL?
AVDL does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.76).
What is the Short Interest ratio of AVDL stock?
The outstanding short interest for AVDL is 13.35% of its float.
AVDL Technical Analysis
AVDL Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to AVDL. AVDL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
AVDL Financial Highlights
Over the last trailing twelve months AVDL reported a non-GAAP Earnings per Share(EPS) of -0.76. The EPS decreased by 65.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -45.86% | ||
| ROE | -97.2% | ||
| Debt/Equity | 0 |
AVDL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to AVDL. The Buy consensus is the average rating of analysts ratings from 16 analysts.
For the next year, analysts expect an EPS growth of 74.6% and a revenue growth 530.17% for AVDL